QC
PACB icon

Quadrature Capital’s Pacific Biosciences PACB Stock Holding History

Quadrature Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Buy
185,654
+73,151
+65% +$106K ﹤0.01% 1189
2026
Q1 		$149K Sell
112,503
-93,907
-45% -$168K ﹤0.01% 1174
2025
Q4 		$386K Sell
206,410
-145,945
-41% -$280K ﹤0.01% 764
2025
Q3 		$449K Buy
+352,355
New +$477K 0.01% 555

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quadrature Capital's PACB Position: Q2 2026 in Review

Quadrature Capital increased its Pacific Biosciences (PACB) stake by 65% in Q2 2026, buying an estimated $106K and bringing the position to 185,654 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #1189.

Quadrature Capital first reported a position in PACB in Q3 2025 and has held it in 4 quarters since. The position peaked at $449K in Q3 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Quadrature Capital held 185,654 shares of Pacific Biosciences worth $312K as of Q2 2026.
  • Quadrature Capital bought 73,151 Pacific Biosciences shares in Q2 2026, an estimated $106K.
  • Pacific Biosciences made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1189 holding.
  • Quadrature Capital first reported a position in Pacific Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Quadrature Capital's Pacific Biosciences position peaked at $449K in Q3 2025.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.